Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7966 to 7980 of 8938 results

  1. Insertion and use of implantable pulmonary artery pressure monitors in chronic heart failure (IPG463)

    Interventional procedures, IPG463 - Issued: August 2013 --> This guidance has been updated and replaced by NICE HealthTech guidance 599.

    Withdrawn guidance

  2. Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus (IPG789)

    We have moved interventional procedures guidance 789 to become HealthTech guidance 723. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    This guidance has been updated and replaced by NICE's highly specialised technologies guidance 34.

    Withdrawn guidance

  4. Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)

    This guidance has been updated and replaced by NICE technology appraisal guidance on dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134).

    Withdrawn guidance

  5. Kidney conditions: CKD and SGLT2 inhibitors (IND322)

    This indicator has been updated and replaced by NICE indicator 324.

    Withdrawn indicator

  6. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)

    This guidance has been updated and replaced by NICE's technology appraisal guidance 1129.

    Withdrawn guidance

  7. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development Reference number: GID-TA10745 Expected publication date:  17 July 2024

    Technology appraisal guidance
    In development

  8. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]

    In development Reference number: GID-TA11805 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]

    Discontinued Reference number: GID-TA11712

    Technology appraisal guidance
    Discontinued

  10. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Discontinued Reference number: GID-TA11396

    Technology appraisal guidance
    Discontinued

  11. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

    Technology appraisal guidance
    Discontinued

  13. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued Reference number: GID-TA10259

    Technology appraisal guidance
    Discontinued

  14. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

    In development Reference number: GID-TA10261 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued Reference number: GID-TA10264

    Technology appraisal guidance
    Discontinued